search
Back to results

Non-invasive Haemodynamic Assessment in Hypertension (FINE-PATH)

Primary Purpose

Arterial Hypertension

Status
Completed
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
lisinopril
Telmisartan
Nebivolol
Indapamide/hydrochlorothiazide
Amlodipine
lisinopril
Telmisartan
Nebivolol
Indapamide/hydrochlorothiazide
Amlodipine
Sponsored by
Military Institute od Medicine National Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Arterial Hypertension focused on measuring arterial hypertension, hemodynamics, impedance cardiography, hypotensive therapy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • untreated AH (elevated BP values ≥ 3 months) and insufficiently controlled AH by one or two antihypertensive drugs.

Exclusion Criteria:

  • confirmed secondary AH,
  • improperly controlled AH with three or more medicines
  • chronic renal failure in the third and higher stages of the disease,
  • other severe concomitant diseases: systolic heart failure, cardiomyopathy, significant cardiac arrhythmia, significant valvular disease, chronic obstructive pulmonary disease (stage C/D), diabetes, previously undetected, polyneuropathy, peripheral vascular disease,
  • body mass index (BMI) > 40 kg/m2,
  • mental illness, preventing cooperation with the physician,
  • heart rhythm other than sinus (including, i.e. constant heart stimulation),

Sites / Locations

  • Military Institute of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Hemodynamic group

Empiric Group

Arm Description

The treatment choice based on hemodynamic parameters established with ICG method. Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg

The treatment choice based on current guidelines (blinded to ICG). Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg

Outcomes

Primary Outcome Measures

24-h mean Systolic Blood Pressure (in ABPM)
24-h mean Diastolic Blood Pressure (in ABPM)
daytime mean Systolic Blood Pressure (in ABPM)
daytime mean Diastolic Blood Pressure (in ABPM)
night-time mean Systolic Blood Pressure (in ABPM)
night-time mean Diastolic Blood Pressure (in ABPM)
Systolic Blood Pressure (in OBPM)
Diastolic Blood Pressure (in OBPM)
24-h mean Systolic Blood Pressure (in ABPM)
24-h mean Diastolic Blood Pressure (in ABPM)
daytime mean Systolic Blood Pressure (in ABPM)
daytime mean Diastolic Blood Pressure (in ABPM)
night-time mean Systolic Blood Pressure (in ABPM)
night-time mean Diastolic Blood Pressure (in ABPM)
Systolic Blood Pressure (in OBPM)
Diastolic Blood Pressure (in OBPM)

Secondary Outcome Measures

change from baseline in Systolic Blood Pressure (in OBPM) at 3 months
change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months
change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months
change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months
change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months
change from baseline in Systolic Blood Pressure (in OBPM) at 3 months
change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months
change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months
change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months
change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months
change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months

Full Information

First Posted
November 18, 2013
Last Updated
March 11, 2018
Sponsor
Military Institute od Medicine National Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01996085
Brief Title
Non-invasive Haemodynamic Assessment in Hypertension
Acronym
FINE-PATH
Official Title
The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
January 2013 (Actual)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Military Institute od Medicine National Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Arterial hypertension (AH) is an important clinical social and economic problem. In the pathogenesis of AH increased BP is a result of complex mechanisms i. e. fluid retention, increased vascular resistance and hyperkinetic heart function. Impedance cardiography (ICG) is a simple and safe, non-invasive method of hemodynamic monitoring which allows simultaneous assessment of i. e. BP, cardiac index, heart rate, the fluid content in the chest and systemic vascular resistance. The detailed effect of treatment based on ICG has not been evaluated so far in the long-term observation and for other clinically relevant parameters, such as central blood pressure, left ventricular hypertrophy, metabolic disturbances, parameters of antioxidative-oxidative balance and endothelial function. Therefore, the following main objectives of the study were defined: Evaluation of usefulness of impedance cardiography in optimizing treatment of patients with hypertension in the area of reduction and control of blood pressure, hemodynamic parameters, biochemical markers and quality of life. Evaluation of complex pathophysiological mechanisms associated with hypertension including hemodynamic, anthropometric, psychological and biochemical parameters as well as the effect of antihypertensive treatment on these phenomena. The study will be randomized (1:1), prospective and controlled in parallel with conventional treatment. The subjects will be divided into groups according to the pre-established random order: empiric group (GE), in which treatment choice will be based on clinical data and current guidelines hemodynamic group (HD), in which treatment choice will be based on clinical data and current guidelines considering hemodynamic parameters established with ICG method. All patients will undergo a detailed examination three times: before treatment, then after 3 and 12 months of treatment. The authors expect that the study will consolidate the importance of ICG in the diagnosis of patients with AH. Simultaneous multiparametric evaluation of the subjects guarantees a unique and innovative results which can enhance our knowledge in pathophysiology of AH and reversibility of adverse mechanisms associated with this disease.
Detailed Description
THE IMPORTANCE OF THE PROJECT. Arterial Hypertension (AH) is an important clinical social and economic problem and a major risk factor of coronary artery disease, heart failure, kidney failure and stroke. The risk of organ damage can be significantly reduced just by achieving proper control of blood pressure (BP). In the pathogenesis of AH increased BP is a result of complex mechanisms i. e. fluid retention, increased vascular resistance and hyperkinetic heart function. Impedance cardiography (ICG) is a simple and safe, non-invasive method of hemodynamic monitoring which allows simultaneous assessment of i. e. BP, cardiac index, heart rate, the fluid content in the chest and systemic vascular resistance. The studies conducted so far (including the applicant's own studies) have demonstrated that ICG provided a better selection of drugs and their doses in the short-term observation. The detailed effect of such treatment strategy has not been evaluated so far in the long-term observation and for other clinically relevant parameters, such as central blood pressure, left ventricular hypertrophy, pulse wave velocity, metabolic disturbances, parameters of antioxidative-oxidative balance and endothelial function. Undoubtedly, such an evaluation may be of high importance in evaluating complex pathophysiological mechanisms associated with cardiovascular hemodynamics. It is expected that the results of this study performed in a group representing a large population of hypertensive patients will allow highly objective, multiparametric evaluation of the usefulness of ICG in hypotensive therapy. The conclusions may be clinically, socially and economically important, especially in terms of effectiveness and continuity of treatment in patients with AH and primary prevention of cardiovascular events and organ damage. THE CONCEPT AND STUDY DESIGN. The main aims: Evaluation of usefulness of impedance cardiography in optimizing treatment of patients with hypertension in the area of reduction and control of blood pressure, hemodynamic parameters, biochemical markers and quality of life. Evaluation of complex pathophysiological mechanisms associated with hypertension including hemodynamic, anthropometric, psychological and biochemical parameters as well as the effect of antihypertensive treatment on these phenomena. The specific aims: Evaluation of the added value of the algorithm of treatment based on the ICG in optimizing treatment of patients with AH in the reduction and control of BP, hemodynamic, biochemical markers and quality of life. Optimization of the used algorithm of antihypertensive treatment on the basis of multiparametric clinical evaluation. Determination of hemodynamic profiles of patients with AH including multiparametric clinical evaluation. Evaluation of complex pathophysiological mechanisms associated with AH including hemodynamic, anthropometric, psychological and biochemical parameters. Evaluation of the impact of antihypertensive treatment on the values of the studied haemodynamic and anthropometric parameters, biochemical markers and quality of life. The study will be randomized (1:1), prospective and controlled in parallel with conventional treatment. Study group will involve 140 patients of both sexes, aged from 18 to 75 years. All patients will undergo a detailed examination three times: before treatment, then after 3 and 12 months of treatment, according to the following protocol. Qualification visit. Clinical assessment with consideration of the criteria of inclusion and exclusion. Presentation of information on the project. First visit (after qualification): physical examination with particular attention to factors of cardiovascular risk, including BP measurement in accordance with the recommendations, standard 12-lead electrocardiogram, echocardiography, 6-minute walk test (6-MWT), impedance cardiography (ICG), measurement of central blood pressure by applanation tonometry, measurement of ankle-brachial index (ABI), ambulatory blood pressure measurement (ABPM), assessment of brachial artery vasodilatation after ischemia (FMD), laboratory tests [wide range], psychological testing, anthropometry, assessment of hemodynamics of retrobulbar vessels with use of color Doppler imaging (CDI) cardiovascular risk assessment - based on the examination and the results of laboratory tests. At the first visit antihypertensive therapy and non-pharmacological treatment (individualized diet, weight reduction, regular physical activity, ceasing smoking) will be recommended. The subjects will be divided into groups according to the pre-established random order (www.randomization.com): empiric group (GE), in which treatment choice will be based on clinical data and current guidelines; hemodynamic group (HD), in which treatment choice will be based on clinical data and current guidelines considering hemodynamic parameters established with ICG method. The choice of treatment in GE group will be performed by a research team member blinded to ICG result. The subjects will not be informed about the type of intervention used. The randomization into the study groups - as on the first visit - will be maintained for all visits. Depending on the values of SVRI, CI, HR and TFC, hemodynamic disturbances are defined as: (1) hemodynamic profile with excessive vasoconstriction (hyperconstrictive, C: in case of SVRI > 2500 dyn•s•cm-5•m2), (2) with hyperdynamic heart function (hyperdynamic, D: CI > 4.2 l/min/m2 and/or HR > 80/min), (3) with characteristics of overhydration (hypervolemic, V: man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm), (4) balanced hemodynamic profile balanced (B, hemodynamic parameters of thresholds predefined below) - angiotensin converting enzyme inhibitors indicated. In STEP 1, when the patient's hemodynamic profile will be hyperdynamic - beta-blocker will be recommended, when hypervolemic -diuretic, when hyperconstrictive - angiotensin converting enzyme inhibitor or angiotensin receptor blocker (if systemic vascular resistance index > 2800 dyn•s•cm-5•m2 - angiotensin converting enzyme inhibitor/angiotensin receptor blocker with calcium blocker recommended). In cases of complex hemodynamic disturbances the combined therapy will be applied. The STEP 2 will be reserved for the patients with relatively high blood pressure (expected reduction ≥ 20/10mmHg, 24-h mean BP ≥ 140/90 mmHg) of when impedance cardiography suggested only one hemodynamic disturbance. They were assumed to demand polytherapy for that reason the second drug will be added to the first chosen in STEP 1 in combinations: beta-blocker with angiotensin converting enzyme inhibitor/angiotensin receptor blocker; angiotensin converting enzyme inhibitor/angiotensin receptor blocker with diuretic; diuretic with angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Second visit (after 3 months of pharmacotherapy): physical examination with particular attention to factors of cardiovascular risk, including BP measurement in accordance with the recommendations, impedance cardiography (ICG), measurement of central blood pressure by applanation tonometry, ambulatory blood pressure measurement (ABPM), laboratory tests [narrow range], psychological testing, anthropometry cardiovascular risk assessment - based on the examination and the results of laboratory tests. Third visit (after 9 months from the second visit, or in cases of hospitalization for cardiovascular reasons): range of examinations and tests as at the first visit, In the course of observation, each patient will have the right to contact research team on his own initiative for questions and concerns related to participation in the study or his health condition. CHARACTERISTICS OF THE MAIN APPLIED RESEARCH METHODS. Laboratory tests will be performed at the Department of Laboratory Diagnostics of Military Medical Institute: [wide range]: blood count, ionogram, creatinine, urea, uric acid, alanine aminotranserase and aspartate aminotranserase, creatine kinase (CK, CK-MB), lipid profile: total cholesterol, LDL and HDL cholesterol, triglycerides, fasting glucose, insulin, glycosylated hemoglobin (HbA1C), lipoprotein (a), leptin, adiponectin; urinalysis, microalbuminuria, homocysteine; high sensitive C-reactive protein (hsCRP), coagulogram, fibrinogen, D-dimer, superoxide dismutase, plasminogen activator inhibitor 1, resistin [narrow range]: blood count, ionogram, creatinine, urea, lipid profile, fasting glucose Impedance cardiography (ICG). On the basis of 10-minute rest recordings of ICG the detailed analysis of mean values of hemodynamic parameters will be performed for: systolic blood pressure (SBP), mean blood pressure (MBP), diastolic blood pressure (DBP), pulse pressure (PP), heart rate (HR), stroke volume (SV) and index (SI), cardiac index (CI), systemic vascular resistance index (SVRI), total artery compliance (TAC) and characteristics of aortic flow: velocity index (VI) and acceleration index (ACI). Final assessment will also include spectral variability of hemodynamic parameters (i. e. HR, CI, SV, SVR). Central blood pressure measurement (applanation tonometry). Non-invasive assessment of central blood pressure and related parameters will be performed using the method of applanation tonometry (SphygmoCor Px Aortic BP Profile System). The parameters derived from aortic blood pressure waveform analysis such as i.e. aortic augmentation index (AAI), central blood pressure (CBP) and central pulse pressure (CPP) will be analyzed. Ambulatory blood pressure monitoring (ABPM). All the patients included in the study will undergo ABPM (Spacelabs 90207; Spacelabs, Medical Inc, Redmond, Washington, USA). The average values of SBP, MBP, DBP, PP (derived from 24-h period, daytime and nightime period) and the corresponding standard deviations (SD) will be analyzed. As the minimum acceptable number of valid BP measurements a 70% is assumed. Echocardiography. Echocardiography will be performed according to current standards with the use of Vivid 7 apparatus (GE-Healthcare, the USA). Measurements connected with size of heart chambers, contractility and left ventricle wall thickness, ejection fraction and left ventricle relaxation disorders will be evaluated and recorded. The examination will also include automated functional imaging (AFI) of left ventricle. Flow-mediated dilatation (FMD). The measurement will be performed in the morning, in a quiet room after 10 minutes of rest in supine position. Evaluation of the brachial artery will be done in a 2-D projection, 3-5 cm above the cubital fossa, with the Doppler linear probe of frequency 8 MHz. Dilation of the brachial artery after ischemia will be expressed as a percentage change in brachial artery diameter induced by ischemia in relation to the diameter of the vessel prior to ischemia, in accordance with generally accepted methodology. Color Doppler Imaging (CDI) of retrobulbar vessels and ophthalmic examination Evaluation of the retrobulbar vessels (ophthalmic artery OA, central retinal artery CRA and short posterior ciliary arteries (temporal and nasal) TSPCA, NSPCA) of the randomly selected eye will be done with the Doppler linear probe of frequency 6-15 MHz (LOGIQ 9 Color Doppler Imaging System; General Electric Medical Systems, Milwaukee, Wisconsin, USA) and will include assessment of peak systolic velocity (PSV), end diastolic velocity (EDV) and resistance index (RI) calculated as follows: RI = (PSV -EDV)/PSV. All subjects underwent also the randomly selected eye examination that included: autorefractometry and air-puff tonometry (TRK-1P, TOPCON Corporation, Tokyo, Japan), slit-lamp and stereo optic disc evaluation and Spectral optical coherence tomography (OCT/SLO) (Ophthalmic Technologies, Inc. OTI, Toronto, ON, CANADA) of the optic nerve head (ONH), retinal nerve fiber layer (RNFL) and macula. DATA ANALYSIS. All results will be archived in the form of extensive database with the possibility of multiple analysis, using advanced data analysis systems, such as Statistica, SPSS, MedCalc. To evaluate of complex pathophysiological mechanisms associated with hypertension including hemodynamic, anthropometric, psychological and biochemical parameters (well as the effect of antihypertensive treatment on these phenomena) the correlations and inter-subgroups comparisons will be performed. The results of detailed ophthalmic examination will be also referred to cardiovascular assessment. MEASURABLE DOCUMENTED EFFECT OF THE PROBLEM. The authors expect that the study will form the basis of the substantive merits of implementing the proposed algorithm of hemodynamic assessment in broad clinical practice as a tool supporting optimization of hypotensive therapy. It is expected that the results will consolidate the importance of ICG in the diagnosis of patients with AH. Simultaneous multiparametric evaluation of the subjects guarantees a unique and innovative results which can enhance our knowledge in pathophysiology of AH and reversibility of adverse mechanisms associated with this disease. It may become an inspiration to undertake further clinical trials related to the practical application of new methods of hemodynamic monitoring.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Hypertension
Keywords
arterial hypertension, hemodynamics, impedance cardiography, hypotensive therapy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hemodynamic group
Arm Type
Experimental
Arm Description
The treatment choice based on hemodynamic parameters established with ICG method. Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg
Arm Title
Empiric Group
Arm Type
Active Comparator
Arm Description
The treatment choice based on current guidelines (blinded to ICG). Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg
Intervention Type
Drug
Intervention Name(s)
lisinopril
Intervention Description
Angiotensin converting enzyme inhibitor recommended in case of: "hyperconstrictive" profile (SVRI > 2500-2800 dyn•s•cm-5•m2) "hyperdynamic" profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol) "hypervolemic" profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic) "balanced" profile
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Description
Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Beta-blocker recommended in case of: 1."hyperdynamic" profile (CI > 4.2 l/min/m2 and/or HR > 80/min)
Intervention Type
Drug
Intervention Name(s)
Indapamide/hydrochlorothiazide
Intervention Description
"hypervolemic" profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) "hyperconstrictive" profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Description
1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
Intervention Type
Drug
Intervention Name(s)
lisinopril
Intervention Description
Drug choice at the discretion of physician (blinded to ICG)
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Description
Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Drug choice at the discretion of physician (blinded to ICG)
Intervention Type
Drug
Intervention Name(s)
Indapamide/hydrochlorothiazide
Intervention Description
Drug choice at the discretion of physician (blinded to ICG)
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Description
Drug choice at the discretion of physician (blinded to ICG)
Primary Outcome Measure Information:
Title
24-h mean Systolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
24-h mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
daytime mean Systolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
daytime mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
night-time mean Systolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
night-time mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 3 months from recruitment
Title
Systolic Blood Pressure (in OBPM)
Time Frame
after 3 months from recruitment
Title
Diastolic Blood Pressure (in OBPM)
Time Frame
after 3 months from recruitment
Title
24-h mean Systolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
24-h mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
daytime mean Systolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
daytime mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
night-time mean Systolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
night-time mean Diastolic Blood Pressure (in ABPM)
Time Frame
after 12 months from recruitment
Title
Systolic Blood Pressure (in OBPM)
Time Frame
after 12 months from recruitment
Title
Diastolic Blood Pressure (in OBPM)
Time Frame
after 12 months from recruitment
Secondary Outcome Measure Information:
Title
change from baseline in Systolic Blood Pressure (in OBPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Systolic Blood Pressure (in OBPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Title
change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months
Time Frame
after 12 months from recruitment
Other Pre-specified Outcome Measures:
Title
Heart Rate (HR)
Time Frame
after 3 months from recruitment
Title
Cardiac Index (CI)
Time Frame
after 3 months from recruitment
Title
Thoracic Fluid Content (TFC)
Time Frame
after 3 months from recruitment
Title
Systemic Vascular Resistance Index (SVRI)
Time Frame
after 3 months from recruitment
Title
augmentation index (AAI)
Time Frame
after 3 months from recruitment
Title
Central Systolic Blood Pressure
Time Frame
after 3 months from recruitment
Title
Central Diastolic Blood Pressure
Time Frame
after 3 months from recruitment
Title
Flow-mediated Dilatation (FMD)
Time Frame
after 3 months from recruitment
Title
Heart Rate (HR)
Time Frame
after 12 months from recruitment
Title
Cardiac Index (CI)
Time Frame
after 12 months from recruitment
Title
Thoracic Fluid Content (TFC)
Time Frame
after 12 months from recruitment
Title
Systemic Vascular Resistance Index (SVRI)
Time Frame
after 12 months from recruitment
Title
augmentation index (AAI)
Time Frame
after 12 months from recruitment
Title
Central Systolic Blood Pressure
Time Frame
after 12 months from recruitment
Title
Central Diastolic Blood Pressure
Time Frame
after 12 months from recruitment
Title
Flow-mediated Dilatation (FMD)
Time Frame
after 12 months from recruitment
Title
left ventricular mass index(LVMI)
Time Frame
after 12 months from recruitment
Title
change from baseline in Heart Rate (HR) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Cardiac Index (CI) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Thoracic Fluid Content (TFC) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Systemic Vascular Resistance Index (SVRI) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in augmentation index (AAI) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Central Systolic Blood Pressure at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Central Diastolic Blood Pressure at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Flow-mediated Dilatation (FMD) at 3 months
Time Frame
after 3 months from recruitment
Title
change from baseline in Heart Rate (HR) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Cardiac Index (CI) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Thoracic Fluid Content (TFC) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Systemic Vascular Resistance Index (SVRI) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in augmentation index (AAI) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Central Systolic Blood Pressure at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Central Diastolic Blood Pressure at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in Flow-mediated Dilatation (FMD) at 12 months
Time Frame
after 12 months from recruitment
Title
change from baseline in left ventricular mass index (LVMI) at 12 months
Time Frame
after 12 months from recruitment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: untreated AH (elevated BP values ≥ 3 months) and insufficiently controlled AH by one or two antihypertensive drugs. Exclusion Criteria: confirmed secondary AH, improperly controlled AH with three or more medicines chronic renal failure in the third and higher stages of the disease, other severe concomitant diseases: systolic heart failure, cardiomyopathy, significant cardiac arrhythmia, significant valvular disease, chronic obstructive pulmonary disease (stage C/D), diabetes, previously undetected, polyneuropathy, peripheral vascular disease, body mass index (BMI) > 40 kg/m2, mental illness, preventing cooperation with the physician, heart rhythm other than sinus (including, i.e. constant heart stimulation),
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pawel Krzesinski, MD, PhD
Organizational Affiliation
Department of Cardiology and Internal Diseases, Military Institute of Medicine, Poland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Military Institute of Medicine
City
Warsaw
State/Province
Mazovia
ZIP/Postal Code
04-141
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
15752931
Citation
Ventura HO, Taler SJ, Strobeck JE. Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005 Feb;18(2 Pt 2):26S-43S. doi: 10.1016/j.amjhyper.2004.11.002.
Results Reference
background
PubMed Identifier
12019280
Citation
Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002 May;39(5):982-8. doi: 10.1161/01.hyp.0000016176.16042.2f.
Results Reference
background
PubMed Identifier
16520405
Citation
Smith RD, Levy P, Ferrario CM; Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group. Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension. 2006 Apr;47(4):771-7. doi: 10.1161/01.HYP.0000209642.11448.e0. Epub 2006 Mar 6.
Results Reference
background
PubMed Identifier
20042450
Citation
Ferrario CM, Flack JM, Strobeck JE, Smits G, Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010 Feb;4(1):5-16. doi: 10.1177/1753944709348236. Epub 2009 Dec 30.
Results Reference
background
PubMed Identifier
15752930
Citation
Ferrario CM. New approaches to hypertension management: always reasonable but now necessary. Am J Hypertens. 2005 Feb;18(2 Pt 2):23S-25S. doi: 10.1016/j.amjhyper.2004.11.042. No abstract available.
Results Reference
background
PubMed Identifier
19253194
Citation
Krzesinski P, Gielerak G, Kowal J. [Impedance cardiography - a modern tool for monitoring therapy of cardiovascular diseases]. Kardiol Pol. 2009 Jan;67(1):65-71. No abstract available. Polish.
Results Reference
background
PubMed Identifier
26876066
Citation
Krzesinski P, Gielerak G, Stanczyk A, Piotrowicz K, Uzieblo-Zyczkowska B, Banak M, Kurpaska M, Michalczyk L, Jurek A, Wolszczak K, Galas A, Wojcik A, Skrobowski A. The effect of hemodynamically-guided hypotensive therapy in one-year observation: Randomized, prospective and controlled trial (FINEPATH study). Cardiol J. 2016;23(2):132-40. doi: 10.5603/CJ.a2016.0009. Epub 2016 Feb 15.
Results Reference
derived

Learn more about this trial

Non-invasive Haemodynamic Assessment in Hypertension

We'll reach out to this number within 24 hrs